Can Gabapentin Cause Tinnitus? What the Science Says

Gabapentin is listed among antiepileptic drugs that can produce tinnitus, hearing changes, and other auditory side effects even at standard therapeutic doses, according to a review of drug safety evidence.¹ Yet the same drug has been trialed repeatedly as a potential tinnitus treatment, making its relationship with ringing in the ears genuinely unusual among medications. The science here is not as simple as “gabapentin causes tinnitus” or “gabapentin treats tinnitus,” and understanding why requires looking at who is taking it, what kind of tinnitus is involved, and how well the kidneys are working.

What the Drug Safety Literature Reports

A review in Expert Opinion on Drug Safety examined the auditory and vestibular side effects of several antiepileptic medications, including gabapentin, carbamazepine, phenytoin, valproate, and lamotrigine. The review concluded that long-term use of these drugs can result in tinnitus, sound sensitivity, sensorineural hearing loss, dizziness, and abnormal conduction along the auditory nerve and brainstem pathways.¹ What makes this finding concerning is that it applies even at normal prescribed doses, not just in overdose situations. The mechanism appears to involve changes in how the cochlea (the inner ear structure that converts sound to nerve signals) and the brainstem auditory pathways process signals.

This does not mean everyone who takes gabapentin will develop ringing in their ears. Tinnitus appears in prescribing information as a known but uncommon side effect, and the drug safety review groups gabapentin with the broader antiepileptic class rather than singling it out as uniquely ototoxic. Still, the evidence that it can happen is not speculative. It has been documented through both clinical observation and objective testing of auditory function in patients on these medications.

The Paradox of Gabapentin as a Tinnitus Treatment

Here is where the story gets interesting. Despite being documented as a possible cause of tinnitus, gabapentin has been tested in multiple clinical trials as a treatment for tinnitus. The rationale was that tinnitus often involves overactive nerve signaling in the auditory system, and gabapentin’s ability to calm nerve activity might help quiet the phantom sounds. In animal research, this idea showed real promise: in one study using a behavioral model of tinnitus in rats, gabapentin reversibly reduced the signs of tinnitus.²

The human trial results, though, have been far less encouraging. A Cochrane systematic review examined seven trials covering four different anticonvulsants, including gabapentin, for tinnitus. Three of those studies used validated questionnaires to measure outcomes. None showed a clear benefit. In one trial, gabapentin actually made tinnitus scores worse compared to placebo. In another, gabapentin showed a small, nonsignificant improvement. When the data from both gabapentin trials were pooled, the net effect was essentially zero.³ A separate systematic review that screened studies specifically for gabapentin reached the same conclusion: the evidence is insufficient to recommend gabapentin for tinnitus patients.⁴ An earlier review found the same, noting that the two double-blind randomized trials meeting its inclusion criteria both reported gabapentin was not better than placebo on their primary outcomes.⁵

So the best available evidence, across multiple systematic reviews, says gabapentin does not reliably treat tinnitus in the general population. The drug that might cause ringing does not appear to quiet ringing either, at least not for most people.

Why Acoustic Trauma Might Be an Exception

One specific group of patients does seem to respond differently. A controlled trial of gabapentin in patients whose tinnitus was caused by acoustic trauma (sudden, loud noise exposure) found that roughly nine out of ten patients in the gabapentin group responded to treatment, compared to about six out of ten in the control group, a statistically significant difference. After six weeks, tinnitus severity scores dropped in both groups, but the drop was significantly larger with gabapentin.⁶

This is a genuinely intriguing result, but it needs context. The trial was relatively small, and the control group also improved substantially, which is common in tinnitus research because the condition naturally fluctuates and responds to placebo. The broader systematic reviews that found no benefit for gabapentin included patients with many different causes of tinnitus, and they lumped acoustic trauma patients together with people whose tinnitus had no identifiable origin. One of the reviews explicitly flagged this problem, noting that there were large differences between studies in tinnitus duration, hearing loss severity, and baseline handicap scores.⁵

The takeaway is that “tinnitus” is not one disease. It is a symptom with many possible origins, and a drug that helps tinnitus from fresh noise damage might do nothing for tinnitus that has been present for years from an unknown cause. This heterogeneity is a persistent problem in tinnitus research, and it likely explains why gabapentin trials have produced such conflicting results.

What Gabapentin Actually Does in the Auditory System

Gabapentin’s main action in the nervous system is binding to a specific part of calcium channels on nerve cells. This slows down the release of certain chemical signals and reduces nerve excitability. In the auditory system, this has two competing implications. On one hand, overactive auditory neurons are thought to generate the phantom sounds of tinnitus, so dampening that activity could theoretically help. On the other hand, the auditory system relies on precise, well-timed nerve signaling, and blunting that signaling too broadly could interfere with normal hearing function.

Research in animal models illustrates this tension. A study testing gabapentin’s effects on auditory processing in gerbils found that the drug did not improve impaired temporal processing in older animals. In young gerbils with normal hearing, gabapentin actually raised thresholds for detecting certain sounds, meaning it made their hearing slightly worse under some conditions. The researchers attributed this to gabapentin’s relatively moderate effects on brain chemistry and its binding to calcium channel subunits.⁷ In short, the drug’s calming effect on nerve activity is a double-edged sword in the auditory system, potentially helpful in some circumstances and harmful in others.

The Dosing Question

Many of the trials testing gabapentin for tinnitus used quite high doses. In one well-known randomized controlled trial, most participants were titrated up to 3,600 mg per day, with a small number reaching only 2,700 mg, 1,800 mg, or 900 mg.⁸ Even at this high dose, the drug did not beat placebo for general idiopathic tinnitus in that trial. Meanwhile, the drug safety review documenting auditory side effects noted that problems could appear at standard therapeutic doses.¹

This creates an uncomfortable situation for patients: the dose range that has been tested for potential tinnitus relief is also a dose range where auditory side effects become plausible. There is no cleanly established “safe” dose below which tinnitus side effects never occur and above which therapeutic benefit kicks in. The evidence simply does not draw that line. If you are taking gabapentin for pain, seizures, or another condition and notice new ringing in your ears, the dose you are on matters, but it is not possible to predict from published data alone whether lowering the dose would help.

When Kidney Function Changes Everything

Gabapentin is cleared from the body almost entirely by the kidneys. When kidney function drops, the drug accumulates and blood levels can climb far higher than intended, even on a standard dose. A published case report describes a woman with diabetes and previously normal kidney function who developed sudden hearing loss, involuntary muscle jerking, confusion, and hallucinations after her kidneys failed acutely. Her gabapentin blood level was measured at 17.6 micrograms per milliliter. After a single session of hemodialysis, her gabapentin level dropped to undetectable, and all of her symptoms, including the hearing loss, resolved within four days.⁹

This case is instructive for a few reasons. First, it demonstrates that gabapentin’s auditory effects can include outright hearing loss, not just tinnitus. Second, the damage was reversible once the drug was removed, suggesting the effect was functional rather than structural. And third, it underscores that people with reduced kidney function are at substantially higher risk for gabapentin toxicity. If you are taking gabapentin and have chronic kidney disease or any condition that affects how well your kidneys work, hearing changes should be reported to your doctor promptly, because the fix may be as straightforward as adjusting the dose.

The Fibromyalgia Overlap

Gabapentin and its close relative pregabalin are commonly prescribed for fibromyalgia, a condition involving widespread pain, fatigue, and sensory hypersensitivity. What makes this relevant to tinnitus is that fibromyalgia itself is strongly associated with ringing in the ears. In one study of fibromyalgia patients, roughly half reported tinnitus.¹⁰ In a pediatric cohort, about a third of young people with juvenile fibromyalgia had tinnitus, compared to just a few percent of those without fibromyalgia.¹¹

This creates a genuine attribution problem. If you have fibromyalgia and started gabapentin and then noticed tinnitus, was it the drug or the disease? The honest answer is that it is often impossible to tell. Fibromyalgia involves a hypersensitized central nervous system, and tinnitus appears to be one of the many sensory symptoms that come along with that sensitization. A patient blaming the drug might stop it unnecessarily; a patient assuming it is just the fibromyalgia might miss a side effect that could be managed with a dose change.

A study that evaluated tinnitus before and after fibromyalgia treatment found that both pregabalin and an antidepressant significantly reduced tinnitus levels in these patients.¹² That result makes sense: if the underlying central sensitization is driving the tinnitus, then treating the fibromyalgia may reduce the tinnitus regardless of which drug is used. It also means that for fibromyalgia patients specifically, gabapentinoids might actually improve tinnitus rather than cause it, adding yet another layer to the paradox.

What the Cochrane Review Tells Us About Anticonvulsants More Broadly

Gabapentin is not the only anticonvulsant that has been tried and found wanting for tinnitus. The Cochrane review on anticonvulsants for tinnitus covered trials of gabapentin, carbamazepine, lamotrigine, and flunarizine, and found no convincing evidence that any of them work.³ The review also flagged that most of the included studies had high or unclear risk of bias, meaning the trial designs were not strong enough to draw firm conclusions either way. With only seven trials and about 450 total patients across all four drugs, the evidence base is thin. Tinnitus research in general suffers from small trial sizes, inconsistent outcome measures, and the fundamental difficulty of measuring a subjective experience.

The broader point is that the “can gabapentin cause tinnitus” question cannot be fully separated from the “does it treat tinnitus” question, because the answer to both shapes how we understand the drug’s relationship with the auditory system. If gabapentin clearly treated tinnitus, the question of it causing tinnitus would be more surprising. Instead, the drug sits in an ambiguous middle ground where it may modestly help certain tinnitus subtypes (possibly acute acoustic trauma), appears to do nothing for the most common forms, and can produce or worsen tinnitus as a side effect in some patients, especially at higher doses or when kidney clearance is impaired.

Practical Steps If You Suspect Gabapentin Is Causing Your Tinnitus

If you are taking gabapentin and have noticed new ringing or worsening of existing ringing, a few considerations are worth keeping in mind:

• Timing matters: Tinnitus that appeared shortly after starting gabapentin or after a dose increase is more likely to be drug-related than tinnitus that has been present for years and happens to be noticed more now.
• Kidney function: If you have any degree of kidney impairment, gabapentin levels can rise unpredictably. A blood test to check kidney function and, in some settings, a gabapentin drug level can help determine whether accumulation is a factor.
• Other medications: Gabapentin is frequently taken alongside other drugs that can cause tinnitus on their own, including certain antibiotics, loop diuretics, and nonsteroidal anti-inflammatory drugs. Before assuming gabapentin is the culprit, a full medication review is warranted.
• The underlying condition: As the fibromyalgia data illustrate, some conditions for which gabapentin is prescribed carry their own risk of tinnitus. Disentangling the drug from the disease often requires a trial of reducing or stopping the medication under medical supervision.

Do not stop gabapentin abruptly. The drug should be tapered gradually to avoid withdrawal symptoms, including seizures in people who take it for epilepsy. Any changes should be discussed with the prescribing clinician, who can weigh the tinnitus concern against the reason you are taking the drug in the first place.

Why Tinnitus Research Keeps Running Into Walls

Tinnitus remains one of the most frustrating conditions in medicine. Roughly one in ten adults experiences it to some degree, yet no drug has been approved specifically for its treatment. The fundamental problem is that tinnitus is a symptom, not a disease: it can arise from damage to the inner ear, from changes in the brainstem, from altered processing in the auditory cortex, or from more diffuse changes in how the brain handles sensory information. A drug like gabapentin that targets one of these mechanisms might help the subset of patients where that mechanism is dominant and do nothing, or even cause harm, in the rest.

Until tinnitus research catches up with more precise ways of classifying patients by the underlying cause of their symptoms, trials will keep producing mixed results. The Cochrane reviewers acknowledged this problem explicitly, noting that the clinical differences between patients within the same trial were large enough to cloud any treatment signal.³ For gabapentin specifically, the pattern of evidence suggests that the drug’s interaction with the auditory system is real but context-dependent, capable of both quieting and generating phantom sounds depending on who is taking it and why.